Wave Life Sciences, Inc. (WVE): Operating Income
-$215.38M
Year ended 2025-12-31
-$217.92M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$215.38M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$110.40M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$68.00M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$162.72M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$127.02M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$153.38M | n/m | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | -$208.32M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$159.52M | n/m | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | -$102.39M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$55.72M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$19.30M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$5.39M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$3.57M | n/a | 2016-03-30, From 2013-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | -$215.38M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$41.98M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$11.35M | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | -$2.71M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | -$2.79M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$71.05M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$68.30M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$158.13M | n/m |
| BGM Group Ltd. (BGM) | 2025-09-30 | -$12.58M | n/m |
Compare WVE, XLO, BFRI, INBP side by side · Screen every company in Pharmaceutical Preparations ↗